Expert:

Prof Julia Scarisbrick

Institution:

University Hospital Birmingham, UK

Speciality:

Dermatology

Therapeutic Areas of interest:

ECP in Dermatologic Diseases

Expertise:

Co-author of the European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis, 2020
Author of The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas, 2022
Co-author of The Role of Extracorporeal Photopheresis in the management of Cutaneous T – Cell Lymphoma, Graft versus Host Disease and Organ Transplant Rejection: A consensus statement update from the UK Photopheresis Society, 2017
Expert in the usage of ECP for CTCL (evidence, guidelines, and novel tools to measure response)

Bio:

Prof Scarisbrick is Consultant Dermatologist at the University Hospital Birmingham and leads the Cutaneous Lymphoma Service
She holds an Honorary Chair at the University of Birmingham in the Institute of Immunology and Immunotherapy
Her research interest is focused on both clinical and molecular research fields for cutaneous lymphoma, she has a successful translational research program, and is involved in the development and delivery of both academic and commercial clinical studies
She is Past Chairperson of the EORTC Cutaneous Lymphoma Group, European Director for Cutaneous Lymphoma International Consortium, Trustee and Past Chairperson for the UK Photopheresis Society, Secretary and Chair Elect for the International Society of Cutaneous Lymphoma and Trustee for the UK Cutaneous Lymphoma Group (Past Chair).
She is involved in the development of clinical guidelines in cutaneous lymphoma, and ECP
In 2015 she was the Chairperson UK Expert of the Photopheresis Group coordinating research projects and developing guidelines (Former chairperson of the group btw 2015 – 2022)

Request to book a session with Prof Julia Scarisbrick

To book an appointment, please make sure you are logged in

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Expert:

Prof Julia Scarisbrick

Expertise:

Bio:

Request to book a session with Prof Julia Scarisbrick

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS